Khng nn t dng thuc khi khng c ch nh ca Bc s
The process often begins with a list of some 1,000 names, according to Scott Piergrossi, president of creative for Brand Institute, a prolific namer of pharmaceuticals
* Results vary from person to person and develop gradually with consistent use
Pricing, doctor access, medications, and patient experience analyzed
These topline results from the Phase 2b VESPER-3 study reinforce the potential of PF3944 as a monthly treatment with competitive efficacy, said Jim List, MD, PhD, Chief Internal Medicine Officer
The medication is not approved by the FDA, which means the FDA has not tested or reviewed it for safety, quality, and effectiveness